PE20030638A1 - Formulacion granular de montelukast sodico - Google Patents

Formulacion granular de montelukast sodico

Info

Publication number
PE20030638A1
PE20030638A1 PE2002001047A PE2002001047A PE20030638A1 PE 20030638 A1 PE20030638 A1 PE 20030638A1 PE 2002001047 A PE2002001047 A PE 2002001047A PE 2002001047 A PE2002001047 A PE 2002001047A PE 20030638 A1 PE20030638 A1 PE 20030638A1
Authority
PE
Peru
Prior art keywords
montelukast sodium
granular formulation
polylivine
refers
substrate
Prior art date
Application number
PE2002001047A
Other languages
English (en)
Inventor
Brian Down
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23329547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030638(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of PE20030638A1 publication Critical patent/PE20030638A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA GRANULACION ORAL DE MONTELUKAST SODICO, QUE COMPRENDE: UN SUBSTRATO QUE FLUYE LIBREMENTE REVESTIDO DE MONTELUKAST SODICO; DONDE, DICHO SUBSTRATO PUEDE SER: MANITOL DESHIDRATADO POR ASPERSION CON UN AGENTE AGLUTINANTE O PEARLITOL SD 200, SELECCIONANDOSE EL AGLUTINANTE DE: CELULOSA HIDROXIPROPILICA, METILCELULOSA HIDROXIPROPILICA, METILCELULOSA, ETILCELULOSA Y POLIVINILPIRROLIDONA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA FLUIDA Y DISPERSABLE QUE COMPRENDE LOS GRANULOS YA DESCRITOS
PE2002001047A 2001-10-26 2002-10-24 Formulacion granular de montelukast sodico PE20030638A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33954901P 2001-10-26 2001-10-26

Publications (1)

Publication Number Publication Date
PE20030638A1 true PE20030638A1 (es) 2003-07-21

Family

ID=23329547

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001047A PE20030638A1 (es) 2001-10-26 2002-10-24 Formulacion granular de montelukast sodico

Country Status (26)

Country Link
US (2) US20030096840A1 (es)
EP (1) EP1441701B1 (es)
JP (1) JP4420671B2 (es)
KR (1) KR101094084B1 (es)
CN (1) CN100591329C (es)
AT (1) ATE385781T1 (es)
AU (1) AU2002333134B2 (es)
BR (1) BR0213477A (es)
CA (1) CA2463947C (es)
CY (1) CY1107400T1 (es)
DE (1) DE60225040T2 (es)
DK (1) DK1441701T3 (es)
EC (1) ECSP045082A (es)
EG (1) EG24380A (es)
ES (1) ES2298431T3 (es)
HR (1) HRP20040367B1 (es)
HU (1) HUP0401670A3 (es)
IL (1) IL161299A0 (es)
MX (1) MXPA04003856A (es)
MY (1) MY148466A (es)
NO (1) NO20042167L (es)
PE (1) PE20030638A1 (es)
PT (1) PT1441701E (es)
SI (1) SI1441701T1 (es)
WO (1) WO2003035036A1 (es)
ZA (1) ZA200402584B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192660A1 (en) * 2003-03-12 2004-09-30 Mullally John P. Protocol for improving vision
PL1863476T3 (pl) * 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
EP3449928A1 (en) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
EP1976522B2 (en) 2005-12-30 2019-07-03 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition containing montelukast
AU2006337648A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of montelukast sodium
CN103349659A (zh) 2006-09-26 2013-10-16 塔罗制药北美有限公司 液体药物组合物以及应用
CA2719246A1 (en) * 2008-03-26 2009-10-01 Taro Pharmaceuticals North America, Inc. Stabilizing lipid compositions for oral pharmaceutical agents
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
WO2009143356A1 (en) 2008-05-21 2009-11-26 Ferring International Center S.A. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
WO2009153305A2 (en) * 2008-06-19 2009-12-23 Sandoz Ag Pharmaceutical compositions of montelukast sodium
BRPI0912589A2 (pt) * 2008-08-18 2015-10-13 Mitsubishi Shoji Foodtech Co Ltd "excipiente para comprimidos composto de novo manitol esférico"
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
PL2552418T3 (pl) 2010-03-29 2017-12-29 Ferring B.V. Szybko rozpuszczająca się kompozycja farmaceutyczna
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
CN102085187B (zh) * 2011-01-27 2012-01-11 海南美大制药有限公司 孟鲁司特钠脂质体固体制剂
KR20140108627A (ko) 2011-07-26 2014-09-12 썬 파마 어드밴스트 리서치 컴패니 리미티드 퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)
WO2013037708A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
WO2013077829A1 (en) 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
EP2872177B1 (en) 2012-07-12 2017-12-20 Ferring BV Diclofenac formulations
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20140072628A1 (en) * 2012-09-12 2014-03-13 Glenmark Generics Ltd. Stable pharmaceutical composition of saxagliptin
CN103520136B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 孟鲁斯特钠脉冲胶囊及其制备方法
CN103520130B (zh) * 2013-10-15 2020-08-04 天垚医药科技发展（上海）有限公司 孟鲁斯特钠择时控释片及其制备方法
CN103520129B (zh) * 2013-10-15 2020-07-31 天垚医药科技发展（上海）有限公司 一种孟鲁斯特钠脉冲释放制剂
CN104644564A (zh) * 2013-11-25 2015-05-27 天津汉瑞药业有限公司 一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
US20160339010A1 (en) 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
CN103720672B (zh) * 2014-01-26 2016-03-16 新疆特丰药业股份有限公司 孟鲁司特钠咀嚼片及其粉末直接压片制备方法
CN104840427B (zh) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
KR101892340B1 (ko) * 2015-03-13 2018-08-27 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
JP6489435B2 (ja) * 2015-04-20 2019-03-27 高田製薬株式会社 モンテルカストナトリウム顆粒製剤
CN107595783A (zh) * 2017-06-01 2018-01-19 合肥远志医药科技开发有限公司 一种孟鲁司特钠颗粒及其制备方法
CN109833302A (zh) * 2017-11-29 2019-06-04 扬子江药业集团有限公司 一种稳定的孟鲁司特钠咀嚼片及其制备方法
CN110787139A (zh) * 2018-08-01 2020-02-14 北京万全德众医药生物技术有限公司 一种孟鲁司特钠药物组合物
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
CN111110679A (zh) * 2018-10-31 2020-05-08 长春海悦药业股份有限公司 一种含有孟鲁司特钠的药物组合物
CN111249238A (zh) * 2020-01-19 2020-06-09 安徽省先锋制药有限公司 一种孟鲁司特钠颗粒制剂方法
US11844792B2 (en) * 2020-07-10 2023-12-19 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
CN111840233B (zh) * 2020-07-29 2022-05-06 浙江诺得药业有限公司 一种孟鲁司特钠固体分散体、其制备方法及其应用
CN114224847B (zh) * 2021-12-07 2023-09-15 哈尔滨珍宝制药有限公司 一种孟鲁司特钠颗粒的制备方法
CN114425040A (zh) * 2022-02-24 2022-05-03 佑华医药科技有限公司 一种孟鲁司特钠颗粒的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
CA1338596C (en) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
DE68916497T2 (de) * 1988-09-30 1994-11-17 Rhone Poulenc Rorer Ltd Pharmazeutisches Granulat.
ATE99545T1 (de) * 1989-03-29 1994-01-15 Takeda Chemical Industries Ltd Zusammensetzung mit einer verbindung der vitamin b-gruppe und ihre herstellung.
JP2800242B2 (ja) 1989-03-30 1998-09-21 大正製薬株式会社 粒剤の製造方法
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH0967247A (ja) 1995-08-31 1997-03-11 Taisho Pharmaceut Co Ltd 均一な微粒子製剤の製造方法
AU709301B2 (en) * 1995-11-02 1999-08-26 Merck Frosst Canada & Co. New technology for wet granulation
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
EP1041990B1 (en) 1997-12-23 2006-06-28 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
US6221880B1 (en) * 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
AT413647B (de) 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US20030031720A1 (en) * 2000-02-24 2003-02-13 Tobias Laich Method for producing pharmaceutical dosage forms
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
AU2002333134B2 (en) 2007-08-02
HRP20040367B1 (en) 2012-07-31
US20080131516A1 (en) 2008-06-05
HUP0401670A3 (en) 2008-08-28
ZA200402584B (en) 2005-06-29
EG24380A (en) 2009-04-05
EP1441701B1 (en) 2008-02-13
ATE385781T1 (de) 2008-03-15
DE60225040T2 (de) 2009-02-26
BR0213477A (pt) 2004-11-03
HRP20040367A2 (xx) 2005-06-30
KR101094084B1 (ko) 2011-12-15
KR20040047961A (ko) 2004-06-05
HUP0401670A2 (hu) 2008-05-28
MXPA04003856A (es) 2004-07-08
DK1441701T3 (da) 2008-05-26
JP4420671B2 (ja) 2010-02-24
CN100591329C (zh) 2010-02-24
CA2463947A1 (en) 2003-05-01
MY148466A (en) 2013-04-30
WO2003035036A1 (en) 2003-05-01
CA2463947C (en) 2009-05-19
ES2298431T3 (es) 2008-05-16
CN1575163A (zh) 2005-02-02
NO20042167L (no) 2004-05-25
ECSP045082A (es) 2004-06-28
IL161299A0 (en) 2004-09-27
CY1107400T1 (el) 2012-12-19
EP1441701A1 (en) 2004-08-04
US20030096840A1 (en) 2003-05-22
US8007830B2 (en) 2011-08-30
SI1441701T1 (sl) 2008-08-31
JP2005510497A (ja) 2005-04-21
PT1441701E (pt) 2008-04-07
DE60225040D1 (de) 2008-03-27

Similar Documents

Publication Publication Date Title
PE20030638A1 (es) Formulacion granular de montelukast sodico
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
DK1246622T3 (da) Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
RS52607B (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING VALSARTAN
EP1698672A3 (de) Beschichtungsmasse mit Biozidmikrokapseln
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
DK1578406T3 (da) Farmaceutisk sammensætning med modificeret frigivelse
HUP0402280A2 (hu) Mikronizált filmképző por, az ezt tartalmazó készítmények, eljárások ezek előállítására, és ezek alkalmazása
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
AR041370A1 (es) Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
CL2007003491A1 (es) Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.
AR054806A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
AR037931A1 (es) Metodo para granulacion humeda de azitromicina
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
DK1142573T3 (da) Farmaceutiske præparater omfattende faropenem-natrium og en diaminacetatforbindelse til forbedring af absorption i mave-tarm-kanalen
GB0004827D0 (en) Compositions
CL2003002301A1 (es) PROCEDIMIENTO DE PREPARACION DE OXIDO DE Cu GRANULADO, QUE COMPRENDE LA GRANULACION DE UN OXIDO DE Cu EN POLVO JUNTO CON 0,3 A 8% DE AGENTE LIGANTE POR PESO DE GRANULOS SECOS, EL QUE ES RESISTENTE A SOLVENTES ORGANICOS.
DE602004021704D1 (de) Wirksubstanzkombination mit einer verbindung mit npy rezeptor-affinität und einer verbindung mit 5-ht6 rezeptor-affinität
ATE301933T1 (de) Akarizidpulver
DE60219462D1 (de) Verdickte wässrige zusammensetzungen
ES2186415T3 (es) Composiciones detergentes y para ablandar el agua.
AR031142A1 (es) Composiciones de limpieza
BRPI0516957A (pt) formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)
BR0215925A (pt) Processo para converter um pó supressor de evaporação inicialmente não larvicida, de rápido espalhamento, em um pó supressor de evaporação larvicida, pó supressor de evaporação larvicida, modificação do processo, método e aperfeiçoamentos

Legal Events

Date Code Title Description
FG Grant, registration